[go: up one dir, main page]

PE20171338A1 - Compuestos y composiciones como inhibidores de quinasa raf - Google Patents

Compuestos y composiciones como inhibidores de quinasa raf

Info

Publication number
PE20171338A1
PE20171338A1 PE2017000445A PE2017000445A PE20171338A1 PE 20171338 A1 PE20171338 A1 PE 20171338A1 PE 2017000445 A PE2017000445 A PE 2017000445A PE 2017000445 A PE2017000445 A PE 2017000445A PE 20171338 A1 PE20171338 A1 PE 20171338A1
Authority
PE
Peru
Prior art keywords
compounds
compositions
phenyl
methyl
kinase inhibitors
Prior art date
Application number
PE2017000445A
Other languages
English (en)
Inventor
Matthew T Burger
Savithri Ramurthy
Benjamin R Taft
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20171338A1 publication Critical patent/PE20171338A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a compuestos de formula I, donde: R1 es H o CH3; R2 es piridinilo o fenilo; X e Y son N o -OCH2CHR3R4; R3 es H u OH; R4 es 2-(fosfonooxi)metil o fosfonooxi; Z es N o CH. Son compuestos preferidos: 2-((4-(2-metil-5-(2-(trifluorometil)isonicotinamido)fenil)-6-morfolinopiridin-2-il)oxi)etil dihidrogeno fosfato; (R)-2-((4-(2-metil-5-(2-(trifluorometil)isonicotinamido)fenil)-6-(3-metilmorfolino)piridin-2-il)oxi)etil dihidrogeno fosfato; entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos son inhibidores de quinasas Raf, siendo utiles en el tratamiento de cancer de mama, tumores gastrointestinales, entre otros
PE2017000445A 2014-09-12 2015-09-11 Compuestos y composiciones como inhibidores de quinasa raf PE20171338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049469P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
PE20171338A1 true PE20171338A1 (es) 2017-09-13

Family

ID=54148595

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000445A PE20171338A1 (es) 2014-09-12 2015-09-11 Compuestos y composiciones como inhibidores de quinasa raf

Country Status (30)

Country Link
US (2) US9573969B2 (es)
EP (1) EP3191472B1 (es)
JP (1) JP6678655B2 (es)
KR (1) KR20170053686A (es)
CN (1) CN107108671B (es)
AP (1) AP2017009830A0 (es)
AR (1) AR101815A1 (es)
AU (1) AU2015313782B2 (es)
BR (1) BR112017004741A2 (es)
CA (1) CA2960971A1 (es)
CL (1) CL2017000541A1 (es)
CO (1) CO2017002292A2 (es)
CR (1) CR20170092A (es)
CU (1) CU20170026A7 (es)
DO (1) DOP2017000066A (es)
EA (1) EA031061B1 (es)
EC (1) ECSP17021897A (es)
ES (1) ES2729243T3 (es)
IL (1) IL250950A0 (es)
MX (1) MX2017003233A (es)
NI (1) NI201700029A (es)
PE (1) PE20171338A1 (es)
PH (1) PH12017500416A1 (es)
SG (1) SG11201701734QA (es)
SV (1) SV2017005405A (es)
TN (1) TN2017000075A1 (es)
TW (1) TWI603977B (es)
UY (1) UY36294A (es)
WO (1) WO2016038581A1 (es)
ZA (1) ZA201701633B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
KR20160122736A (ko) * 2014-01-14 2016-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
TWI798218B (zh) 2017-05-02 2023-04-11 瑞士商諾華公司 組合療法
EP3661516A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
JP2022525885A (ja) * 2019-03-22 2022-05-20 キネート バイオファーマ インク． Ｒａｆキナーゼの阻害剤
AU2020268814A1 (en) 2019-05-03 2021-12-16 Kinnate Biopharma Inc. Inhibitors of RAF kinases
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
KR20220104702A (ko) * 2019-10-24 2022-07-26 킨네이트 바이오파마 인크. Raf 키나제의 억제제
US20230046018A1 (en) * 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022066580A1 (en) * 2020-09-23 2022-03-31 Kinnate Biopharma Inc. Raf degrading compounds
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
CA3216104A1 (en) * 2021-04-23 2022-10-27 Aleksandra Franovic Treatment of cancer with a raf inhibitor
KR20240000540A (ko) * 2021-04-23 2024-01-02 킨네이트 바이오파마 인크. (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
JP2024519306A (ja) * 2021-05-12 2024-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ｃＧＡＳ阻害薬としてのＮ結合環状置換基を有するピリジン誘導体

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1998008845A1 (en) 1996-08-27 1998-03-05 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
JP4713698B2 (ja) 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6465493B1 (en) 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
US6310574B1 (en) 1999-08-05 2001-10-30 Vega Grieshaber Kg Level transmitter
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
ES2298165T3 (es) 1999-11-22 2008-05-16 Smithkline Beecham Plc Derivados de imidazol.
CA2397686A1 (en) 2000-01-18 2001-07-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AU2001232809A1 (en) 2000-01-18 2001-07-31 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
US7235658B2 (en) 2000-03-06 2007-06-26 Smithkline Beecham P.L.C. Imidazol derivatives as Raf kinase inhibitors
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP4217480B2 (ja) 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
ES2323421T3 (es) 2002-09-18 2009-07-15 Pfizer Products Inc. Nuevos compuestos de oxazol como inhibidores del factor de crecimientotransformador (tgf).
JP4547271B2 (ja) 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
JP4758349B2 (ja) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2004281151A1 (en) 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of Raf kinase
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
BRPI0508397A (pt) 2004-03-05 2007-08-07 Taisho Pharmaceutical Co Ltd derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
EP1786802A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
WO2007118149A2 (en) 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
RU2479580C2 (ru) 2007-06-27 2013-04-20 Астразенека Аб Производные пиразинона и их применение для лечения легочных заболеваний
WO2009006404A2 (en) 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
JP2010531850A (ja) 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
NZ582708A (en) 2007-07-19 2012-04-27 Schering Corp Heterocyclic amide compounds as protein kinase inhibitors
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
UY31322A1 (es) 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CN102015686B (zh) 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2726158A1 (en) 2008-06-11 2009-12-17 Dana Farber Cancer Institute Compounds and compositions useful for the treatment of malaria
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA3013000C (en) 2008-12-19 2022-12-13 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
JP2012514044A (ja) * 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JP2013503194A (ja) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆキナーゼを阻害するための１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン化合物
CA2771563A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
EP2498608A4 (en) 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
EA022458B1 (ru) 2009-12-28 2016-01-29 Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн 1,3,4-оксадиазол-2-карбоксамидное соединение
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR20140117684A (ko) 2010-06-25 2014-10-07 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
MX339937B (es) 2011-09-01 2016-06-17 Novartis Ag * Compuestos y composiciones como inhibidores de la quinasa c-kit.
CN102993199A (zh) * 2011-09-09 2013-03-27 山东轩竹医药科技有限公司 杂环取代的吡啶并吡咯激酶抑制剂
BR112014006743A8 (pt) 2011-09-21 2018-01-09 Cellzome Ltd composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
IN2014MN02126A (es) 2012-05-02 2015-09-11 Lupin Ltd
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
TW201414704A (zh) 2012-07-02 2014-04-16 Biogen Idec Inc 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
UY36294A (es) 2016-04-29
EP3191472A1 (en) 2017-07-19
TW201613945A (en) 2016-04-16
BR112017004741A2 (pt) 2017-12-05
AR101815A1 (es) 2017-01-11
EA031061B1 (ru) 2018-11-30
TN2017000075A1 (en) 2018-07-04
ZA201701633B (en) 2018-05-30
AP2017009830A0 (en) 2017-03-31
CR20170092A (es) 2017-05-08
MX2017003233A (es) 2017-05-23
AU2015313782B2 (en) 2018-09-13
US20160075727A1 (en) 2016-03-17
CN107108671A (zh) 2017-08-29
ECSP17021897A (es) 2018-02-28
WO2016038581A1 (en) 2016-03-17
JP2017528475A (ja) 2017-09-28
JP6678655B2 (ja) 2020-04-08
SV2017005405A (es) 2018-04-04
EA201790599A1 (ru) 2017-06-30
DOP2017000066A (es) 2017-04-16
CL2017000541A1 (es) 2017-08-18
US9573969B2 (en) 2017-02-21
CU20170026A7 (es) 2017-07-04
EP3191472B1 (en) 2019-03-06
CN107108671B (zh) 2019-10-01
CO2017002292A2 (es) 2017-06-20
KR20170053686A (ko) 2017-05-16
PH12017500416A1 (en) 2017-07-17
IL250950A0 (en) 2017-04-30
CA2960971A1 (en) 2016-03-17
US9809610B2 (en) 2017-11-07
AU2015313782A1 (en) 2017-03-30
US20170114083A1 (en) 2017-04-27
SG11201701734QA (en) 2017-04-27
ES2729243T3 (es) 2019-10-31
NI201700029A (es) 2017-04-04
TWI603977B (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
PE20171338A1 (es) Compuestos y composiciones como inhibidores de quinasa raf
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
PE20191137A1 (es) Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1)
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
JP2017528475A5 (es)
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
NZ711376A (en) Heteroaryl compounds and uses thereof
EA201301302A1 (ru) Производные пиридина и пиразина
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы

Legal Events

Date Code Title Description
FD Application declared void or lapsed